TABLE 1.
Plasma lipids, apoA-I, and hepatic mRNA levels of apoA-I−/− or apoA-I−/− × apoE−/− mice expressing WT and the mutant form of apoA-I as indicated
| Treatment | None | WT ApoAI | ApoA-I[225–230] | ApoA-I[225–230] + LCAT |
| ApoAI −/− mice | ||||
| ApoA-Ih mRNA levels (%) | Nondetectable | 100 ± 15a | 130 ± 10b | 80 ± 10 |
| Plasma apoA-Ih protein (mg/dl) | Nondetectable | 173 ± 63 | 59 ± 17c | 149 ± 43 |
| Plasma cholesterol (mg/dl) | 27 ± 8 | 182 ± 82d | 41 ± 12d,e | 297 ± 69d |
| Plasma triglycerides (mg/dl) | 34 ± 14 | 39 ± 15 | 42 ± 14 | 48 ± 21 |
| ApoAI −/− × apoE −/− mice | ||||
| ApoA-Ih mRNA levels (%) | Nondetectable | 100 ± 21a | 140 ± 50 | 90 ± 30 |
| TC (mg/dl) | 337 ± 107 | 520 ± 85 | 377 ± 90 | 778 ± 103d,e |
| TG (mg/dl) | 58 ± 23 | 680 ± 290d | 35 ± 22e | 87 ± 65e |
Values are means ± SD based on analysis of 5–8 mice per experiment.
Expression of WT apoA-I in the apoA-I−/− or apoA-I−/− × apoE−/− was set to 100%. Expression of LCAT was also confirmed by RT-PCR. Statistical significant differences at P < 0.05 were calculated between untreated mice and mice expressing the WT apoA-I and the apoA-I[F225A/V227A/F229A/L230A] in either the apoA-I−/− or apoA-I−/− × apoE−/− mouse background and are indicated as follows: bP ≤ 0.05 relative to WT apoA-I control; cP ≤ 0.05 relative to WT apoA-I control; dP ≤ 0.05 relative to the untreated control; eP ≤ 0.05 relative to WT apoA-I control.